Researchers Identified New Uveal Melanoma Targets
Scientists found that inhibiting p300 and CBP proteins can impair tumor growth in GNAQ-driven uveal melanoma.
Updated on Oct. 2, 2026 in Cancer
Researchers have identified the proteins p300 and CBP as critical synthetic lethal vulnerabilities for uveal melanoma driven by GNAQ mutations. This discovery offers a new strategy for treating the most common intraocular cancer in adults by targeting the signaling pathways that fuel tumor growth.
Why it matters
Uveal melanomas rely on unrestrained YAP signaling for progression, making these proteins potential therapeutic targets. Inhibiting this mechanism could provide a path to stop tumor growth and metastasis in patients.
The study utilized an isogenic CRISPR screening approach to confirm that p300 and CBP support YAP-dependent transcription. The interaction of these proteins enhances H3K27 acetylation at the promoters of oncogenic target genes.
The details
By using genetic and pharmacological inhibition, researchers demonstrated that p300 and CBP are essential for the recruitment of RNA polymerase II and CDK9. This interruption effectively blocks the signals that GNAQ-driven cancers require to replicate and spread throughout the body.
Timeline
October 2, 2026: The research findings were published.
The Big Picture
This study advances the field of oncology by mapping the regulatory circuitry of the YAP signaling pathway. It establishes a clear mechanistic link between protein acetylation and the progression of GNAQ-driven uveal melanoma.
This research provides a foundational target for future drug development efforts that could one day lead to novel treatment options for uveal melanoma. Patients currently managing this diagnosis should consult with their oncologists regarding clinical trial availability for targeted therapies.
The takeaway
Targeting protein acetylation represents a promising shift in treating aggressive intraocular cancers. Future studies will determine if these laboratory results translate into effective patient therapies.
Further reading
For more on ongoing oncology developments, visit the Cancer section.
More information
Review the full findings in the peer-reviewed research article.
Source note: This article includes information reported by Nature.
